The Institute for Clinical and Economic Review on Wednesday, Oct. 31, released a draft scoping document which lays out its planned review of Janssen’s esketamine.
Esketamine is under review by the Food and Drug Administration for treatment-resistant depression, and is expected to be approved some time in May.
The report, according to ICER, will be discussed at the May 2019 meeting of the Midwest Comparative Effectiveness Public Advisory Council.
“Stakeholders are encouraged to submit comments and suggested refinements to the scope to ensure all perspectives are adequately considered,” ICER states in a press release.
Deadline for comments is 5 p.m. EST on Nov. 20.
To read the draft scoping document, click here.